Materials

Blog

1 of 1 results found
During a challenging year, M&A activity in pharmaceutical markets was lower than experts estimated. Also, there were not many megadeals in Q1 and Q2 compared with 2019 (where the value of the largest deal was $99.5 billion). The biggest deals in the first half of 2020 were Thermo Fisher Scientific / Qiagen ($11.5 billion, COVID-19), Gilead Sciences / Forty Seven ($4.9 billion, oncology), Gilead Sciences / Pionyr Immunotherapeutics ($1.7 billion, oncology), Novo Nordisk / Corvidia ($2.1 billion, cardiometabolic diseases), Eli Lilly / Dermira ($1.1 billion, immunology, dermatology).
Expert at the BRICS Competition Centre